Well, welcome to our webcast of the Genus Interim results for our 2023 Fiscal Year. Thank you for joining Alison Henriksen and me today. As well as our recorded webcast, there's gonna be a live question and answer session held later today, and details are in our results release. After the usual disclaimer on chart two, I'm gonna be covering our business and strategic progress, and Alison's going to outline the financial performance. However, before we start into the presentation, I want to comment briefly on the announcement made this morning that I've decided to retire from Genus on the 30th of September. I joined Genus 10 years ago. It's something, you know, I still find hard to believe just how fast time has flown. It's really been a tremendous privilege to lead such a talented group of people and, together with them, develop Genus into what it is today, a leading global agricultural biotechnology business. However, you know, the march of time affects us all, and as I'm hitting my mid-sixties, I feel the time is right to plan my retirement from a full-time executive role and pursue some other interests. The board has commenced a search for my replacement, and I'm committed to continue to drive the execution of our successful strategy and ensure a smooth transition when a successor has been identified. Look, enough of all of that. Let's look at the headlines of our H1 FY23 performance. We made some good financial and strategic progress. Revenue grew 25%, adjusted EPS grew 15%. Our performance in PIC China improved. We also saw good growth in many other parts of our business. In fact, our PIC business had a record half-year profit. Alison's gonna give further details of the financial results a little bit later. We've really achieved these results in markets which continue to remain quite challenging. I'm gonna give you an overview of our assessment of those market conditions around the world on the next chart. Our progress, I think, was underpinned by market share gains with key customers globally, who are recognizing the strength of our genetics and the great services our Genus colleagues provide. We've also continued to invest in our supply chain, our systems, in research and development to support future growth. I'm pleased with the progress we're making. Our PRRSv resistance program, that continues to progress, and I'm gonna give you some further information on that in a few slides' time. I want to thank my Genus colleagues for their commitment and passion in pursuing our consistent strategy and delivering this strong performance. Let's first understand a bit more about what is happening in our customers' markets and the challenges they're facing. Looking around the world, North American producers made good returns in the last six months, but the market's looking a bit less favorable going forward. There's been some modest expansion of sow numbers and dairy cows, but the beef herd has actually contracted quite a bit due to drought conditions in many beef-raising areas. In Latin America, we saw actually very tough trading conditions in both dairy and beef markets, particularly in Brazil. There are a combination of drought, oversupply, weak domestic demand. That all affected producers and drove a downturn in the market for bovine genetics. I'd say that economic and political uncertainty in that region remains quite high. In Europe, the pig industry has continued to contract in the last year, and I think further decline is really likely. However, dairy producers benefited from high prices, and so that enabled them to be profitable despite high input costs. Finally, in Asia, the China porcine market has continued to be very volatile, while China dairy production has continued to expand, and conditions in Australia have been favorable. To summarize, the global picture's always quite complex, but I would say that conditions for our customers in several quite important markets, are really still challenging. Let's look at China porcine in particular in more detail during the period. What we saw was producers became profitable. The chart here shows you the ratio of pig price to corn price, and if you're above a ratio of six, then generally producers are making money. You can see that as the pig price rose in the autumn of 2022, that started to happen. Producers actually started to hold back pigs to grow them to heavier weights in the hope of even higher prices later. That strength, however, didn't last, as China experienced waves of COVID lockdowns. Through December and running up to the Chinese New Year, the pig price actually started dropping. Due to a combination of oversupply from those heavy pigs now coming onto the market and the strong wave of ASF in parts of China, it came down quite sharply. In addition, the loosening of COVID controls resulted in mass infection throughout China, that depressed demand. What you've seen is the price has been unexpectedly volatile in the last few months. It really begs the question, where to from here? I think those of us that have been around this market long enough know that it's always likely to retain its capacity to surprise us. However, industry experts believe that the price should recover during the H2 of our fiscal year as the supply glut clears and demand strengthens with China normalizing in its post-COVID environment. Let's now think about how our business there has been progressing. We made good progress, particularly with robust royalty revenues. We're also encouraged by the pipeline of new business prospects, although the timing of deliveries is uncertain and depends a bit, I think, on the shape of the market recovery that we see. We're pleased to have started stocking a new nucleus farm at Hong Kong to improve our supply base. Unfortunately, however, one of our joint venture farms did get hit in this wave of ASF in January, and we've had to partially clear and clean up that farm. We anticipate we're gonna be able to cover the supply of breeding stock from other farms, but we're gonna incur some costs for cleaning up the disease. Well, before we look further at the progress we've been making in PIC, I wanted to just remind you of the fundamental strengths of the business. Our strategic competitive advantage is driven by this combination of the best genetics in the industry, deep long-term relationships with the majority of the world's leading producers, an unmatched global supply chain in terms of both size and quality, and pioneering technology. All of that is really underpinned and couldn't have been accomplished without a world-class team of dedicated, passionate people. Let's see how that is adding up to a winning combination. Starting with PIC in North America, I think we're clearly gaining market share in both the sire line and dam line based on the strength of our product performance backed up by outstanding technical service. The PIC 800, which we introduced following the Møllevang acquisition, is continuing to win in customer trials, demonstrating it's simply the best Duroc boar on the market, gaining share with top producers. Our PIC 337 boar also continues to be very strong. The Camborough sow continues to lead in the female side of the market, and that's been driving share gains from internal programs. You recall the transaction we did with Olymel last year and our integration of their AlphaGene program is progressing ahead of plan, both operationally and financially. The results of these gains are now clearly showing through in accelerating North America volumes and our fastest rate of royalty growth there at 10% for many years. You can see similar progress in Latin America driven by some of the same themes. We're illustrating here two case studies. First, in Mexico, we had no business with the 2nd largest producer some years ago. However, our persistence in demonstrating product performance in several trials, our capability to provide technical support to help them through a disease challenge, that's led us to capturing 100% of both the maternal sow and terminal boar business. The 2nd case study is the largest producer in Ecuador. They've been a customer for over 20 years. They operate to great standards, and that enables them to really realize and see the genetic potential of the improvement we're delivering to them. You can see that every year over the last five years, they've achieved more weaned pigs, better feed efficiency, faster growth. I think what you can see here is great genetics, great people, customer relationships, all combining here in these examples to deliver growth. Let's look at how we're further strengthening our global supply chain to power even more growth and competitive advantage going forward. Since 2019, we've expanded our global elite farm capacity by over 75%. The farms we've most recently commissioned include Atlas in Canada, now fully operational. A second nucleus, Genesis, in Brazil, that's ready to be stocked now. Hong Kong in China, which is in the course of being stocked also right now. Notice how in each of these sites, we're working on raising the bar on environmental standards from the outset to make them as low carbon operations as we can. Our PRRSv project continues to make steady progress. We've significantly expanded our E2 generation of animal numbers, and we're now giving birth to the E3 generation. We commissioned an additional farm this autumn to house the growing number of animals. Meanwhile, our productive relationship with the FDA continues. We've had the first three submissions accepted and are well progressed with two further submissions. You can see them on the chart here, phenotypic characterization and food safety. We expect that we'll be making the formal submissions on those two very shortly. Meanwhile, studies are continuing on the last two of the submissions, that's the phenotypic and genotypic durability, and we're discussing the design of the final regulatory studies in these areas with the FDA. Our plan remains to complete all submissions by the end of this calendar year. We're increasing our engagement with international regulatory agencies, and we're seeing encouraging progress here. Let's switch focus to ABS. We've been building our strategic platform in a very similar way to PIC. Strong genetics, long-term relationships, a global supply chain, and significant investment in technology. Once again, this is all realized and enabled by our highly talented team. Let's start with the genetics. Our dairy genetics continue to be very competitive for profit-oriented producers. We have a very broad range of sires lines within the portfolio and are strongly leading the industry in the development of polled genetics. These are the genetics where the cows, they won't have horns, and so they won't need to be dehorned by the farmer, so there's an animal welfare benefit here. In fact, ABS has over 90% of the top polled Net Merit sires in the industry. In beef, our proprietary genetics continue to show great performance, and we're also developing polled genetics here in the T15 line. Those are the white ones, while the T14 line, those are the black ones, they're already naturally polled. Let's take a look at how we're progressing in the market in North America. Alison is gonna share with you a bit more the financial results for North America, but I want to really illustrate how we're winning with a case study. Here you can see however, a number of years through demonstrating performance, providing strong service, and working in partnership with the customer, we've been able to move from doing no business to doing 100% of the business. It's wins like this that are also contributing to driving up the share of Sexcel and beef on dairy in our North America business. A number of you will also be familiar with the idea that we want to create and capture more value for our NuEra beef on dairy genetics by working across whole supply chains where the quality of the genetics can be really appreciated. We're making progress. In North America, a number of these networks are developing. For example, Schmucker Family Farms. They raise cattle, they send them to JBS to be slaughtered. They recognize the quality and cost benefits of NuEra Genetics. Working with them, we're now creating dedicated flows of NuEra beef on dairy animals into their system, enabling us to win new customers and to capture more value. Similarly, in the U.K., we're growing with Warrendale to create a dedicated supply of premium beef for a leading retailer, again, enabling us to recruit more farms onto ABS genetics and capture more value. Look, we've talked about PIC, we've talked about ABS. I want to just remind you of the innovation platform we've built in research and development. We've used this chart several times before to show how we've organized our R&D teams around four key development platforms, all supported by our genome science and bioinformatics teams. The strength and depth of our organization and talent has advanced substantially over recent years. I'm encouraged and excited by the progress they're making across the pipeline of opportunities they're working on. We also collaborate with several leading universities and research institutes to broaden the reach of our efforts. An example of the commercial impact coming from our R&D teams is the expansion of our sexed semen business. We achieved continued growth in the H1, both in sales of Sexcel and in our third-party business, which we call IntelliGen. In EMEIA, we're establishing three new laboratories in the H2 of this fiscal year with new customers who've signed multi-year deals. Meanwhile, our business in India commenced producing and selling sexed semen under a Government of India umbrella contract aimed at accelerating the adoption of sexed semen, which today is very low in what is a very large market, the Indian dairy market. Finally, in this segment of the presentation, I'd like to just wrap us up by commenting on sustainability. I think as you know, genetic improvement drives sustainability for our customers, enabling them to produce protein with fewer resources. That's less land, less water, and lower carbon emissions. In addition, we're committed to reducing the carbon footprint of our own operations, and we're investing behind both of these themes. You can see on the left of the chart, our testing facility for beef bulls recently opened just outside York, where we've installed state-of-the-art feed and water monitoring systems to enable more accurate genetic selection for feed efficiency in our T15 NuEra line. On the right, what you can see is the manure management system at our new Ankang elite farm in China. It represents a huge step forward compared with the farm it replaces, and it demonstrates that we're strongly committed to achieving our 2030 goals to reduce our own carbon emissions by at least 25% and to target net zero by 2050. Let me now hand over to Alison to take you through the financials. Thank you, Stephen. We're all animal lovers at Genus, I've shared with you in the past stories of some of our bovine and porcine stars. As Stephen said, it's our people that make it all happen, we're focused on attracting and developing the best talent. On this page, I'm sharing with you a picture of the 30 interns that joined us for work experience in the U.S. last summer. The program has been very successful, with many of the interns continuing to work with us while completing their studies. Genus has been recognized for the innovative approach taken to support the new generation of talent into the workforce. Really great work done by our recruitment team. For now, let's get into the numbers. Overall, the half-year results were good, it's great to be back in growth. In some markets, it's been tough, particularly in Latin America for ABS and Europe for PIC. There were strong performances in North America by both businesses, and PIC China had seen a gradual recovery. In actual currency, adjusted profit before tax of GBP 42.2 million was up 14%, and this includes net finance costs of GBP 6 million, more than double in the prior period due to rising interest rates and higher debt. The graph to the right shows adjusted operating profit increasing to just shy of the peak in FY21 at GBP 48.3 million. Operating profit margin was down at 13.8%, This was impacted by an 86% increase in gene editing costs as we move towards regulatory approval. PIC China improved its profit, their margins were not at the levels seen in FY21 during the peak. This period, there was a GBP 4.8 million exchange rate benefit on the translation of overseas profits, primarily from sterling weakening against Latin American currencies. Unfortunately, this gain was mostly eaten up by high interest. At today's spot rates, we estimate that the benefit for the full year will be around GBP 6 million-GBP 8 million. As you heard, we're making good progress with the PRRS program, and we've expanded our porcine supply chain. We invested GBP 42.5 million in R&D. That's up 35% on prior period. I'll share some of the specifics of this later. Central costs were 6% up on prior year, reflecting higher accruals for performance-related employee rewards. Looking at performance in constant currency, adjusted operating profit excluding gene editing costs was up 15%, and that's above our medium-term target of 10% CAGR growth. Turning to volumes. Porcine volumes grew 5%, with North America a key driver at 11% growth. China returned to volume growth up 23% and contributed a fifth of PIC's growth. In bovine, we achieved 4% volume growth. This was due to continued growth in sexed genetics, and from a regional perspective, North America led the way with 24% growth in sex volumes. Beef volumes were flat, with Latin America a key driver of growth in prior periods. Overall, Latin America's volume was down 3%, with embryo volumes particularly affected by the challenging market conditions. As I said before, I want to show you what happened to PIC China versus the rest of the group. In the graph on the left, you can see the adjusted operating profit trend of Genus, excluding PIC China and gene editing costs. Solid growth of 12% was achieved in the period. Whilst the margin at 14.2% was higher than FY21, it was 150 basis points down on prior period, that's due to increased investments in other areas of R&D and a lower margin in our ABS business, which I'll talk more about later. On the right-hand side of this slide, you can see what happens to PIC China's performance. The graph on the top shows the causes of period on period improvement in PIC China's profit from GBP 1 million to almost GBP 9 million. There's been good growth in royalty income, that was achieved as customers commenced populating farms. Supply chain costs were lower due to by-product sales margin being almost GBP 2 million higher than prior period. That's because the average peak price was CNY 23 per kilo in the H1. If you recall, PIC China's profits were impacted in the prior period by a one-time refund to a customer of GBP 3.7 million. The graph in the bottom right shows the volume trends, where you can see in the H1, volume grew 23% compared with prior period, although that volume is similar to the H2 of FY22. Upfront breeding stock sales and volume continues to be below levels seen in previous years. This is partly due to PIC's focus on growing business with customers through royalty contracts, also the recovery of the porcine market has been very gradual. The recent dramatic drop in the peak price to CNY 14 per kilo has created a lot of uncertainty in the porcine market. Industry expectations are that the market will start to improve in the spring. As Stephen said, it's difficult to call. PIC delivered a strong performance, hitting a new half-year record with royalty revenue up 14% and growth in royalty revenue in all the regions. Adjusted operating profit margin improved to 39.2%, although not back to the level in FY21, when more margin was achieved in China and Europe's margin was also down a little in the period. The changes in operating profit shown here are in constant currency, as I think they give a better indicator of underlying performance across the regions. North America hit another record of growth, with operating profit up 14% on prior period as they continued to take market share and benefit from sales to Olymel. Royalty revenue growth was also strong at 10%. Latin America's profit was up 12%, with growth achieved by all countries in the region. Our joint venture with Agroceres in Brazil saw profit up 8% on prior period. Europe's profit was 5% down, despite growth achieved in revenue and volumes. We've continued to achieve growth in Spain and profit was flat in Russia, but other countries were challenged, in particular Germany and the U.K. Lastly, as you've heard, China's performance had a large impact on Asia's results, with overall growth of 154%. Now, ABS had mixed performances in the H1. As you can see in the table on the left, there was strong revenue growth, up 23%. The shift to higher price sexed genetics has continued, and this, along with robust price increases, particularly in Europe and North America, meant cost inflation was recovered. However, adjusted operating profit increased 2%. In the chart on the right, I want to show you why this has happened. Firstly, strong profit growth was delivered by North America, Europe and Asia, and I'll talk more about these regions in a moment. However, Latin America, which has been a strong driver of growth in prior periods, suffered an 18% decline in profit in constant currency. The effects of inflation on both supply and demand in the beef and dairy markets, combined with the drought conditions, made it very difficult. Actually, in Brazil, beef consumption per capita dropped to its lowest level in 25 years. ABS saw in Latin America a decline in demand for genetics, with volume down 3% and with higher priced embryo volumes declining by 24%. There was also business cost inflation that had an adverse impact. Production costs were higher than the prior period by GBP 1.2 million, and this is predominantly due to an under absorption of semen straw production costs in June and July last year, which was due to a slowdown in volumes produced. In other words, it was a manufacturing volume variance, and this primarily arose due to the IT incident temporarily impacting the software that's used across the production operations. This was resolved and therefore not an ongoing issue. We've talked before about ABS's digital strategy. There are new associated costs which were incurred by the business as digital platforms have been rolled out across the regions. In some cases, these investments have been made ahead of generating revenue. Moving now to the ABS regional performances with the profit changes shown here in constant currency. North America achieved record growth of 26%. That's the highest they've achieved in more than nine years. We've talked before about the investment made in growing the strategic account sales team to win with the large producers. It takes time to build these relationships. I'm absolutely delighted for the team to see the progress that has been made. This, together with growth in IntelliGen third-party business, meant revenue was up 18%. Sex volumes grew very strongly at 24%, while beef volumes were down 4% against a very high prior period compare. EMEA's revenue was up 10% and profit up 8%, even though total volumes were down 2%, and that's due to really robust price increases to offset inflation. Sexcel continued to grow at 13% and beef volumes were up 6%, particularly across France, Northern Ireland and Russia. As you heard from Stephen, IntelliGen third-party business also grew in the region. Asia continued to achieve good growth in operating profit, up 11%. China and Australia experienced double-digit growth in volumes and profits. China's gradually shifting dairy demand to Sexcel, while Australia promoted Sexcel and NuEra very well. Overall, R&D increased in actual currency GBP 11 million- GBP 42.5 million, and it's important to note half of this growth reflects the impact of ex-FX translation. The growth in spend was as planned, with the largest drivers being expansion of PIC supply chain and the PRRS program as we progress to FDA approval. Porcine product development was up 12%, reflecting investment in digital tools for trait capture amongst other genetic developments, and the increase of elite animals since Atlas Farm became fully operational. As you heard from Stephen, we have expanded our activities in relation to obtaining regulatory approval for the PRRS peak, including increasing our population of gene-edited pigs by over 50% in the period. Consequently, our gene editing spend was up GBP 4 million, which is what we expected. Bovine product development spend was stable, reflecting continued investment in intelligent production enhancements and our dairy and beef development programs. Other research increased 17%, supporting the R&D pipeline, particularly in the field of reproductive biology. We consistently measure and report adjusted results as we think these give a better view of the business' underlying performance. Our statutory results are affected by a number of non-cash items, and I will talk you through these. Statutory profit before tax decreased to GBP 15 million and profit after tax on a statutory basis was GBP 12 million. The adjusted tax rate was 24.2%. That's down 90 basis points compared with the prior period and due to lower deferred tax charges on previously unrecognized losses. Those of you that are familiar with our accounts will know that we are required in our statutory accounts to apply IAS 41, which is accounting for biological assets. The effect was a GBP 17 million decrease, of which GBP 15 million is due to the application of higher discount rates to the valuation of the biological assets. The discount rates simply reflect higher global interest rates. Those of you who followed us for some time know these fair value calculations can fluctuate and are non-cash movements. Exceptional expenses of GBP 2.2 million are principally in relation to the legal costs for the ongoing litigation with STgenetics. Included within that is a credit of GBP 900,000 being the net effect of settlement of the '987 patent and Indian patent disputes. This is further explained in the accounts. Finance costs were up GBP 3.4 million. That's a 126% increase, that reflects higher interest costs on higher debt levels than prior period. Before we take a look at the movements in our net debt, I wanted to talk about free cash flow. You can see in the table on the left, our operating cash flow was GBP 25.7 million, reflecting cash conversion of 62%. This is comparable with the prior period, I expect by June we should reach our annual target of at least 90%. Free cash flow was an outflow of GBP 3 million, which was a significant improvement on the prior period when it was an outflow of GBP 16 million. The drivers of change in the cash flows are shown in the chart to the right. What you can see is that EBITDA was up GBP 10.5 million and spend on CapEx was GBP 12.8 million lower than the prior period. If you recall, FY22 was a peak year of investments in our porcine and bovine facilities. Working capital movements was an increase in outflows of GBP 2.6 million, which primarily reflect the timing of payables and an increase in IntelliGen equipment held in advance of delivery to our third-party customers. Good advances have been made in reducing day sales outstanding and inventory months on hand are stable. In the prior period, we had the benefit of one-time cash receipt of GBP 3.6 million from a legacy legal claim in Brazil, and we are now bearing high interest in tax payments of circa GBP 3.5 million. I expect free cash flow to improve further in the H2 with growth in EBITDA and good working capital management. CapEx for the full year will be around GBP 40 million. You can see on this chart, we ended the half year with net debt of GBP 214 million. Our leverage moderately increased from 1.7-1.8 x EBITDA and remains within our target range of 1-2 x. At the 31st of December, the headroom on our credit facilities was GBP 103 million. With increased debt and high interest rates, I expect we will have higher finance costs in the H2, and it will be up for the full year by around GBP 8 million. This is higher than previous expectations due to higher rates and the FX translation of US dollar interest into sterling. Despite this, improved free cash flows in the H2 should lead to leverage decreasing to around 1.6 x EBITDA by the end of this fiscal year. Given our solid financial position, we propose our interim dividend remains flat compared with prior period, which is 2.8 x adjusted earnings cover, and that's within our targeted range of 2.5 to 3 x. Before I finish, I wanted to say on behalf of everyone at Genus that we feel very privileged to have Stephen as our CEO, and it is our pleasure to work with him. There are many reasons I say that, but the one I want to share is that Stephen is unwavering in his commitment to invest for the long term, regardless of what's happening in the short term, whether this be investing in our people, animals, research, or our facilities. For all of us, that is very motivating. We're not saying any farewells just yet. We've got more to do together in the coming months. I'll now hand over to Stephen to conclude our presentation. Okay. Well, thank you, Alison, very much. Thank you for those kind remarks at the end, particularly. Look, we've covered a lot in this presentation. I'm just gonna summarize very briefly. I think what you can see here is we've achieved good results in the H1, both financially and in terms of strategic progress. Our market and geo-political conditions remain challenging and volatile for customers in many parts of the world, but our performance has been strong in North America and w e expect this to continue. I think more broadly, our strong product portfolio, our depth of talent, it just gives us confidence that we're gonna continue to make good strategic and financial progress. Our overall performance expectations for FY23 are unchanged. Thank you for joining us, and we look forward to answering your questions in the online Q&A coming up.